Floatz logo

VEMURAFENIB

Bladder Cancer

Genentech, Inc.Small moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
73/ 100

Competitive context

122 Active assets in the Bladder Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →